Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson’s Disease

키워드

참고문헌 (54)

1. De Lau LM, "Epidemiology of Parkinson’s disease", Lancet Neurol, 5, pp.525~535 (2006)
2. Jankovic J, "Parkinson’s disease : clinical features and diagnosis", J Neurol Neurosurg Psychiatry, 79, pp.368~376 (2008)
3. Spillantini MG, "Alpha-synuclein in Lewy bodies", Nature, 388, pp.839~840 (1997)
4. Burré J, "The synaptic function of α-synuclein", J Parkinsons Dis, 5, pp.699~713 (2015)
5. Karpinar DP, "Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson’s disease models", EMBO J, 28, pp.3256~3268 (2009)
6. El-Agnaf OM, "Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease", FASEB J, 20, pp.419~425 (2006)
7. Mollenhauer B, "α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism : a cohort study", Lancet Neurol, 10, pp.230~240 (2011)
8. 박민정, "Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson’s Disease", Journal of Clinical Neurology, 7(4), pp.215~222 (2011), 대한신경과학회
9. Lashuel HA, "The many faces of α-synuclein : from structure and toxicity to therapeutic target", Nat Rev Neurosci, 14, pp.38~48 (2013)
10. Stenmark H, "Rab GTPases as coordinators of vesicle traffic", Nat Rev Mol Cell Biol, 10, pp.513~525 (2009)
11. Dalfó E, "Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice", J Neuropathol Exp Neurol, 63, pp.302~313 (2004)
12. Gao Y, "The emerging role of Rab GTPases in the pathogenesis of Parkinson’s disease", Mov Disord, 33, pp.196~207 (2018)
13. Wilson GR, "Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology", Am J Hum Genet, 95, pp.729~735 (2014)
14. Atashrazm F, "LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson’s disease patients", Mov Disord, 34, pp.406~415 (2019)
15. mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human, "Biochem J", 2018, 1861~1883
16. Kiral FR, "Rab GTPases and membrane trafficking in neurodegeneration", Curr Biol, 28, pp.R471~R486 (2018)[DOI]
17. Lai YC, "Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1", EMBO J, 34, pp.2840~2861 (2015)
18. Yamano K, "Endosomal Rab cycles regulate Parkin-mediated mitophagy", Elife, 7, pp.e31326~ (2018)
19. Rivero-Ríos P, "The G2019S variant of leucine-rich repeat kinase 2(LRRK2)alters endolysosomal trafficking by impairing the function of the GTPase RAB8A", J Biol Chem, 294, pp.4738~4758 (2019)
20. Bae EJ, "LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation", Nat Commun, 9, pp.3465~ (2018)
21. Madero-Pérez J, "Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation", Mol Neurodegener, 13, pp.3~ (2018)
22. Fujimoto T, "Parkinson’s disease-associated mutant LRRK2 phosphorylates Rab7L1and modifies trans-Golgi morphology", Biochem Biophys Res Commun, 495, pp.1708~1715 (2018)
23. Purlyte E, "Rab29 activation of the Parkinson’s disease-associated LRRK2 kinase", EMBO J, 37, pp.1~18 (2018)
24. Jeong GR, "Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration", Mol Neurodegener, 13, pp.8~ (2018)
25. Chutna O, "The small GTPase Rab11 co-localizes with α-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity", Hum Mol Genet, 23, pp.6732~6745 (2014)
26. Chiu CC, "Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson’s disease", Oncotarget, 7, pp.54215~54227 (2016)
27. Pagan FL, "Improving outcomes through early diagnosis of Parkinson’s disease", Am J Manag Care, 18, pp.S176~S182 (2012)[DOI]
28. Tolosa E, "The diagnosis of Parkinson’s disease", Lancet Neurol, 5, pp.75~86 (2006)
29. Yang SY, "Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles", J Nanobiotechnology, 14, pp.41~ (2016)
30. 신혜원, "Drug-Induced Parkinsonism", Journal of Clinical Neurology, 8(1), pp.15~21 (2012), 대한신경과학회
31. Chiu CC, "PARK14(D331Y)PLA2G6 causes early-onset degeneration of substantia nigra dopaminergic neurons by inducing mitochondrial dysfunction, ER stress, mitophagy impairment and transcriptional dysregulation in a knockin mouse model", Mol Neurobiol, 56, pp.3835~3853 (2019)
32. Chiu CC, "Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism", Exp Neurol, 263, pp.244~253 (2015)
33. Schapira AH, "Science, medicine, and the future : Parkinson’s disease", BMJ, 318, pp.311~314 (1999)
34. Schlesinger I, "Uric acid in Parkinson’s disease", Mov Disord, 23, pp.1653~1657 (2008)
35. Brodacki B, "Serum interleukin(IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism", Neurosci Lett, 441, pp.158~162 (2008)
36. Scalzo P, "Serum levels of interleukin-6 are elevated in patients with Parkinson’s disease and correlate with physical performance", Neurosci Lett, 468, pp.56~58 (2010)
37. Godau J, "Increased serum insulin-like growth factor 1 in early idiopathic Parkinson’s disease", J Neurol Neurosurg Psychiatry, 81, pp.536~538 (2010)
38. Cui SS, "Serum soluble lymphocyte activation gene-3 as a diagnostic biomarker in Parkinson’s disease : a pilot multicenter study", Mov Disord, 34, pp.138~141 (2019)
39. Marques TM, "Serum NFL discriminates Parkinson disease from atypical parkinsonisms", Neurology, 92, pp.e1479~e1486 (2019)[DOI]
40. Bagheri V, "CXCL12 and CXCR4 in the peripheral blood of patients with Parkinson’s disease", Neuroimmunomodulation, 25, pp.201~205 (2018)
41. Niimi Y, "Altered regulation of serum lysosomal acid hydrolase activities in Parkinson’s disease : a potential peripheral biomarker", Parkinsonism Relat Disord, 61, pp.132~137 (2019)
42. Pavlos NJ, "Quantitative analysis of synaptic vesicle Rabs uncovers distinct yet overlapping roles for Rab3a and Rab27b in Ca2+-triggered exocytosis", J Neurosci, 30, pp.13441~13453 (2010)
43. Gerges NZ, "Local control of AMPA receptor trafficking at the postsynaptic terminal by a small GTPase of the Rab family", J Biol Chem, 279, pp.43870~43878 (2004)
44. Mignogna ML, "The intellectual disability protein RAB39B selectively regulates GluA2 trafficking to determine synaptic AMPAR composition", Nat Commun, 6, pp.6504~ (2015)
45. Mori Y, "Small GTPase Rab17 regulates the surface expression of kainate receptors but not α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid(AMPA)receptors in hippocampal neurons via dendritic trafficking of Syntaxin-4 protein", J Biol Chem, 289, pp.20773~20787 (2014)
46. Shin N, "LRRK2 regulates synaptic vesicle endocytosis", Exp Cell Res, 314, pp.2055~2065 (2008)
47. Shi MM, "Rab GTPases : the key players in the molecular pathway of Parkinson’s disease", Front Cell Neurosci, 11, pp.81~ (2017)
48. Williams SM, "Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson’s and Alzheimer’s diseases", Eur J Neurosci, 43, pp.3~16 (2016)
49. Brigo F, "Differentiating drug-induced parkinsonism from Parkinson’s disease : an update on non-motor symptoms and investigations", Parkinsonism Relat Disord, 20, pp.808~814 (2014)
50. Wu Y, "Preclinical biomarkers of Parkinson disease", Arch Neurol, 68, pp.22~30 (2011)
51. Sherer TB, "Biomarkers for Parkinson’s disease", Sci Transl Med, 3 (2011)[DOI]
52. Haehner A, "Prevalence of smell loss in Parkinson’s disease--a multicenter study", Parkinsonism Relat Disord, 15, pp.490~494 (2009)
53. Ravina B, "The impact of depressive symptoms in early Parkinson disease", Neurology, 69, pp.342~347 (2007)
54. Delenclos M, "Biomarkers in Parkinson’s disease: advances and strategies", Parkinsonism Relat Disord, 22(Suppl 1), pp.S106~S110 (2016)

관련 논문AI추천